Ndagi U - Search Results

1

Re-emergence of an orphan therapeutic target for the treatment of resistant prostate cancer - a thorough conformational and binding analysis for ROR-γ protein.

Ndagi U, Mhlongo NN, Soliman ME. Ndagi U, et al. J Biomol Struct Dyn. 2018 Feb;36(2):335-350. doi: 10.1080/07391102.2016.1277555. Epub 2017 Jan 16. J Biomol Struct Dyn. 2018. PMID: 28027708

2

The impact of Thr91 mutation on c-Src resistance to UM-164: molecular dynamics study revealed a new opportunity for drug design.

Ndagi U, Mhlongo NN, Soliman ME. Ndagi U, et al. Mol Biosyst. 2017 May 30;13(6):1157-1171. doi: 10.1039/c6mb00848h. Mol Biosyst. 2017. PMID: 28463369

3

Emergence of a Promising Lead Compound in the Treatment of Triple Negative Breast Cancer: An Insight into Conformational Features and Ligand Binding Landscape of c-Src Protein with UM-164.

Ndagi U, Mhlongo NN, Soliman ME. Ndagi U, et al. Appl Biochem Biotechnol. 2018 Jul;185(3):655-675. doi: 10.1007/s12010-017-2677-z. Epub 2017 Dec 27. Appl Biochem Biotechnol. 2018. PMID: 29282631

4

Metal complexes in cancer therapy - an update from drug design perspective.

Ndagi U, Mhlongo N, Soliman ME. Ndagi U, et al. Drug Des Devel Ther. 2017 Mar 3;11:599-616. doi: 10.2147/DDDT.S119488. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28424538 Free PMC article. Review.

5

A consequence of drug targeting of aminoacyl-tRNA synthetases in Mycobacteriumtuberculosis.

Ndagi U, Kumalo HM, Mhlongo NN. Ndagi U, et al. Chem Biol Drug Des. 2021 Sep;98(3):421-434. doi: 10.1111/cbdd.13865. Epub 2021 Jul 3. Chem Biol Drug Des. 2021. PMID: 33993612 Review.

6

An analogue of a kinase inhibitor exhibits subjective characteristics that contribute to its inhibitory activities as a potential anti-cancer candidate: insights through computational biomolecular modelling of UM-164 binding with lyn protein.

Ndagi U, Abdullahi M, Hamza AN, Soliman ME. Ndagi U, et al. RSC Adv. 2019 Dec 24;10(1):145-161. doi: 10.1039/c9ra07204g. eCollection 2019 Dec 20. RSC Adv. 2019. PMID: 35492550 Free PMC article.

7

Ursolic acid as a potential inhibitor of Mycobacterium tuberculosis cytochrome bc1 oxidase-a molecular modelling perspective.

Tembe N, Machaba KE, Ndagi U, Kumalo HM, Mhlongo NN. Tembe N, et al. Among authors: ndagi u. J Mol Model. 2022 Jan 13;28(2):35. doi: 10.1007/s00894-021-04993-w. J Mol Model. 2022. PMID: 35022913

8

Antibiotic resistance: bioinformatics-based understanding as a functional strategy for drug design.

Ndagi U, Falaki AA, Abdullahi M, Lawal MM, Soliman ME. Ndagi U, et al. RSC Adv. 2020 May 14;10(31):18451-18468. doi: 10.1039/d0ra01484b. eCollection 2020 May 10. RSC Adv. 2020. PMID: 35685616 Free PMC article. Review.

9

Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment.

Adeowo FY, Oyetunji TP, Ejalonibu MA, Ndagi U, Kumalo HM, Lawal MM. Adeowo FY, et al. Among authors: ndagi u. Chem Biodivers. 2021 Nov;18(11):e2100361. doi: 10.1002/cbdv.202100361. Epub 2021 Oct 20. Chem Biodivers. 2021. PMID: 34547176

10

Density functional theory study of gold(III)-dithiocarbamate complexes with characteristic anticancer potentials.

Lawal MM, Lawal IA, Klink MJ, Tolufashe GF, Ndagi U, Kumalo HM. Lawal MM, et al. Among authors: ndagi u. J Inorg Biochem. 2020 May;206:111044. doi: 10.1016/j.jinorgbio.2020.111044. Epub 2020 Feb 24. J Inorg Biochem. 2020. PMID: 32120162

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters